Inactive Instrument
Norda ASA Stock Oslo Bors
Stocks
NORD
NO0010285190
Biotechnology & Medical Research
| Market Cap | 513M 51.81M 45.35M 41.86M 39.05M 73.57M 4.9B 74.88M 502M 195M 2.42B 195M 190M 8.42B | P/E 2023 * |
-
| P/E 2024 | 3.26x |
|---|---|---|---|---|---|
| Enterprise Value | 264M 26.69M 23.36M 21.56M 20.11M 37.9M 2.52B 38.58M 259M 100M 1.25B 100M 98.02M 4.34B | EV / Sales 2023 |
-1.24x | EV / Sales 2024 | 0.4x |
| Free-Float |
6.26% | Yield 2023 * |
-
| Yield 2024 | 32.5% |
| 04-09 | Exercise of Warrants by primary insiders | AQ |
| 10/07/25 | Mandatory Notification of Trade | AQ |
| 04/06/25 | Ocean Sun: Mandatory notification of trade | AQ |
| 27/03/25 | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | AQ |
| 03/03/25 | Notification of trade | AQ |
| 1 day | +3.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 08/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 31/01/2014 | |
| Director/Board Member | 68 | 20/06/2013 | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.37% | -6.12% | - | - | 44.67M | ||
| +1.15% | +5.94% | -3.40% | +2.32% | 46.62B | ||
| -2.46% | +10.91% | +411.01% | +602.80% | 40.95B | ||
| +0.11% | +13.12% | +22.95% | -13.80% | 32.26B | ||
| -1.58% | +3.51% | +18.07% | +60.30% | 32.24B | ||
| -3.29% | +2.85% | +13.80% | +30.30% | 25.53B | ||
| +1.86% | +12.14% | - | - | 16.38B | ||
| +0.45% | +13.19% | +70.76% | +123.15% | 15.27B | ||
| +0.56% | +5.09% | +13.43% | +17.88% | 13.61B | ||
| -0.47% | +5.58% | +103.06% | +95.54% | 13.34B | ||
| Average | -0.01% | +10.33% | +81.21% | +114.81% | 26.24B | |
| Weighted average by Cap. | -0.55% | +10.36% | +95.47% | +138.59% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 86.92M 8.77M 7.68M 7.09M 6.61M 12.46M 830M 12.68M 85.05M 33.02M 409M 32.97M 32.23M 1.43B | 372M 37.54M 32.86M 30.33M 28.29M 53.31M 3.55B 54.26M 364M 141M 1.75B 141M 138M 6.1B |
| Net income | 31.17M 3.15M 2.75M 2.54M 2.37M 4.47M 298M 4.55M 30.5M 11.84M 147M 11.82M 11.56M 512M | 126M 12.71M 11.13M 10.27M 9.58M 18.06M 1.2B 18.38M 123M 47.84M 593M 47.77M 46.7M 2.07B |
| Net Debt | -311M -31.42M -27.5M -25.39M -23.68M -44.62M -2.97B -45.42M -305M -118M -1.47B -118M -115M -5.11B | -249M -25.12M -21.99M -20.3M -18.93M -35.67M -2.38B -36.31M -243M -94.51M -1.17B -94.37M -92.26M -4.08B |
Employees
-
















